The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...

Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...

The use of Dupixent in AD has set a high benchmark ... pharmaceutical companies are investigating agents with different mechanisms of action to provide alternatives to the current standard of ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold ... enthusiasm about the progress of this mechanism of action. Positive outcomes from clinical trials ...